Ann: ResApp Presentation at TechKnow Invest Roadshow, page-5

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 5 Last

Share
Profile

Follow
cyrus79

113 Posts.

4

30/10/18

18:28

Post #: 36319797
Share

Originally posted by RNClarke ↑

I attended the Techknow Investor Roadshow and spoke to both Keating and Leedman at length around today’s announcement.

In a nutshell these results will comfortable allow us to submit and move forward with three critical diseases in the US. URTI, Lower Respiratory Tract infection along with a regulatory submission for asthma.

These three are the most commercially lucrative. Telehealth companies are after a quick differentiation between lower and upper respiratory tract infection which will determine whether or not a patient needs to see a doctor and go through standard testing. Remember ResApp is an aid to diagnosis!

To everyone’s main question: Why the discrepancy between Australians and US results?

A lot of the cases failed to reach a consensus between the adjudication panel (which is why the confidence intervals were low). Additionally the numbers were extremely small for pneumonia so a handful number of patients were able to swing the accuracy numbers considerably.

Keating mentioned he was able to explain each pneumonia adjudication decision case by case.

In the US, classifications of respiratory disease is heavily based around X-Rays and clinical procedures. In the Australian studies clinicians based their adjudication decisions around all available testing equipment (and are a lot more accurate imo).

Keating expects Croup results which will come out shortly to also be high enough for a submission as the subjectivity isn't determined by a multitude of tests in the US, its primarily by doctors.

Today's sell off was a complete market overreaction. The company is well funded, pursuing FDA submissions for numerous diseases along with TGA/CE clearance and will be revenue generating next year. Sleep Apnoea and monitoring of chronic diseases are also being pursued, there will be plenty of newsflow.

There will be heavy bounce in the coming sessions especially post the conference call tomorrow. Complete market overreaction for a product which will have FDA approval shortly.

P.S Nice to see everyone there @Red bar @gothechooks @MrBenny @Rudy1 @minimogul and many others.

Expand

""These three are the most commercially lucrative "". thats the take home sentence every one needs to know here . 80 percent of cases is just that and thats enough . The US is smart and want to slowly introduce it into the system .RAP is here to stay like i said before its another buying time for me . thank you sellers

RAP Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

Making money: How many microcaps should be in an investor's portfolio?

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

What each US election outcome would mean for Australian companies & investors

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch